Flag of the European Union EU Clinical Trials Register Help

Clinical trials for EDSS

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    439 result(s) found for: EDSS. Displaying page 1 of 22.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-021978-11 Sponsor Protocol Number: 101MS326 Start Date*: 2011-05-04
    Sponsor Name:Biogen Idec Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis
    Medical condition: Secondary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) FI (Completed) CZ (Prematurely Ended) DK (Prematurely Ended) BE (Prematurely Ended) ES (Completed) PL (Prematurely Ended) IT (Prematurely Ended) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004935-18 Sponsor Protocol Number: GNC-004 Start Date*: 2017-04-12
    Sponsor Name:GeNeuro SA
    Full Title: A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis
    Medical condition: Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) HR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020338-25 Sponsor Protocol Number: WA25046 Start Date*: 2010-11-02
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis
    Medical condition: Primary Progressive Multiple Sclerosis (PPMS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) ES (Ongoing) BE (Completed) FR (Completed) HU (Completed) NL (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PT (Completed) AT (Completed) FI (Completed) IT (Completed) GR (Completed) BG (Completed) DK (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005418-31 Sponsor Protocol Number: COMB157G2301 Start Date*: 2016-10-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) HU (Completed) GB (Completed) SE (Completed) DK (Completed) CZ (Completed) SK (Completed) ES (Completed) NL (Completed) EE (Completed) BG (Completed) GR (Completed) PL (Completed) HR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001224-22 Sponsor Protocol Number: 215MS202 Start Date*: 2017-12-28
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as ...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10067063 Progressive relapsing multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) BE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000700-29 Sponsor Protocol Number: MD1003CT2016-01MS-SPI2 Start Date*: 2017-02-01
    Sponsor Name:MEDDAY PHARMACEUTICALS SA
    Full Title: Effect of MD1003 in progressive multiple sclerosis: a randomized double-blind placebo-controlled study.
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) DE (Prematurely Ended) ES (Prematurely Ended) HU (Completed) BE (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003706-33 Sponsor Protocol Number: 28821 Start Date*: 2009-03-24
    Sponsor Name:Merck Serono S.A. - Geneva
    Full Title: A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS
    Medical condition: Subjects with a first clinical demyelinating event (Clinically Isolated Syndrome (CIS)) at high risk of converting to Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) FI (Prematurely Ended) EE (Prematurely Ended) AT (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) NO (Prematurely Ended) BE (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) GR (Completed) FR (Completed) SE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006107-15 Sponsor Protocol Number: 21-PP-23 Start Date*: 2022-01-17
    Sponsor Name:University Nice Hospital
    Full Title: LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS: CONSONANCE EXTENSION STUDY
    Medical condition: progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005419-33 Sponsor Protocol Number: COMB157G2302 Start Date*: 2016-10-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BE (Completed) FI (Completed) GB (Completed) AT (Completed) CZ (Completed) PT (Completed) SK (Completed) ES (Completed) LV (Completed) LT (Completed) BG (Completed) FR (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002113-35 Sponsor Protocol Number: MD1003CT2013-02MS-SPI Start Date*: Information not available in EudraCT
    Sponsor Name:MEDDAY SAS
    Full Title: Effect of MD1003 in spinal progressive multiple sclerosis: a pivotal randomized double blind placebo controlled study
    Medical condition: Progressive spinal multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001511-73 Sponsor Protocol Number: WA40404 Start Date*: 2019-12-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
    Medical condition:
    Disease:
    Population Age: Gender:
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) PT (Trial now transitioned) IE (Completed) DE (Completed) BG (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) HU (Completed) HR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002357-35 Sponsor Protocol Number: CRO1959 Start Date*: 2012-10-23
    Sponsor Name:Imperial College London
    Full Title: Stem cells in Rapidly Evolving Active Multiple Sclerosis (STREAMS)
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000888-15 Sponsor Protocol Number: ESTUDIO CORTEM Start Date*: 2008-05-19
    Sponsor Name:Servicio de Neurología
    Full Title: ENSAYO CLÍNICO, MULTICÉNTRICO, CON ASIGNACIÓN ALEATORIA Y DOBLE CIEGO, PARA COMPARAR LA EFICACIA CLÍNICA Y RADIOLÓGICA DE DOSIS EQUIVALENTES DE METILPREDNISOLONA ADMINISTRADAS POR VÍA ORAL O VÍA IN...
    Medical condition: Pacientes afectos de esclerosis múltiple
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003226-19 Sponsor Protocol Number: MS-LAQ-301 Start Date*: 2007-09-05
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: Study Title: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laq...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) GB (Completed) FR (Completed) CZ (Completed) LV (Completed) AT (Completed) LT (Completed) ES (Completed) EE (Completed) PT (Prematurely Ended) SE (Completed) IT (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002627-32 Sponsor Protocol Number: 2007-002627-32 Start Date*: 2009-02-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5mg fingolimod administered orally once daily versus placebo in patients wit...
    Medical condition: Primary progressive multiple sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) FI (Completed) SE (Completed) ES (Completed) FR (Completed) IT (Completed) DE (Completed) NL (Completed) BE (Completed) HU (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002728-33 Sponsor Protocol Number: CUPID2005 Start Date*: 2006-02-28
    Sponsor Name:Plymouth Hospitals NHS Trust
    Full Title: Cannabinoid Use in Progressive Inflammatory brain Disease
    Medical condition: Progressive multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000283-41 Sponsor Protocol Number: FUMAPMS2016 Start Date*: 2016-09-12
    Sponsor Name:Finn Sellebjerg
    Full Title: Dimethyl fumarate treatment of primary progressive multiple sclerosis
    Medical condition: Primary progressive multiple sclerosis (PPMS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000647-30 Sponsor Protocol Number: EFC16645 Start Date*: 2020-08-27
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis
    Medical condition: Non-relapsing Secondary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) FR (Completed) DE (Restarted) GB (GB - no longer in EU/EEA) CZ (Completed) NO (Completed) FI (Completed) DK (Completed) BE (Completed) LT (Completed) AT (Completed) GR (Completed) NL (Completed) PT (Completed) PL (Completed) HU (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000518-13 Sponsor Protocol Number: 2011-398 Start Date*: 2012-06-21
    Sponsor Name:Prof. Per Soelberg Sørensen
    Full Title: Immunomodulating and neuroprotective properties of autologous multipotent mesenchymal stem cells in patients with multiple sclerosis - A randomised placebo-controlled double-blinded phase II study
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001965-34 Sponsor Protocol Number: oral-CORTEM Start Date*: 2012-11-07
    Sponsor Name:Servicio de Neurología, HU. Germans Trias i Pujol
    Full Title: Multicenter, randomized, double-blind clinical trial to compare the clinical and radiological efficacy of 625 mg vs 1250 mg of oral methylprednisolone in patients with multiple sclerosis in relapse.
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 13:17:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA